Bexa reduces the cost of early detection by 75% to 80%, in two ways: a lower cost per exam and greatly fewer false positive examinations than any other technology. Bexa is a small, highly portable device that requires no special facility (no radiation, no biohazard and no big capital investment), but instead just a place that a woman can be examined in private. The exam is performed and results are easily interpreted by a trained non-physician examiner. Training requires about two weeks and is provided by Sure, Inc.

When participation in early detection is low, 55% to 80% of women are diagnosed with late-stage cancer. Bexa can be deployed widely due to low operating cost and minimal staff expense, and can be operated in non-intimidating, community-based settings that dramatically increase women’s adoption of the procedure. 95% of women, from Quito to Lagos to Sharja and beyond respond very favorably to the Bexa experience and will endorse the procedure to their friends and family.

Early detection services that are not widely adopted do not significantly affect population health costs. It’s time that we open our collective eyes to the realities of most breast cancer screening programs: they fail to engage the majority of women. Breast cancer screening programs that rely solely upon a single, expensive, poorly adopted modality, fail women and fail the payors of healthcare. Without widespread adoption, there’s no widespread impact on health or care costs.

To be very clear: mammograms have saved hundreds of thousands of lives and we are in no way “anti-mammogram.” But we insist upon being “pro-reality,” and that reality is that despite intense promotion the adoption of mammography by women in most countries is poor, and availability is limited. Expanding access and adoption requires an additional modality. Bexa is a highly adopted, low-cost, accurate early detection modality.